GlassScriptPhysician profile
Kimberly D Daniels
NPI 1184074197
$14,058.30
in general payments reported to CMS, 2019-2025
42 companies · $2,966 in 2025
The $2,966 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,102 · 2022: $2,751 · 2023: $3,315 · 2024: $2,924 · 2025: $2,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,065 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,065.18 |
| Education | $139.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,698.13 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,920.54 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,136.10 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $571.21 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Intercept Pharmaceuticals, INC. | $491.31 | 2021-2025 | Ocaliva |
| Pfizer INC. | $459.38 | 2021-2025 | |
| Gilead Sciences, INC. | $432.77 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $393.08 | 2022-2025 | Dupixent |
| Amgen INC. | $384.03 | 2021-2024 | Repatha, Otezla, Amjevita |
| Ardelyx, INC. | $366.16 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $350.19 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $318.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $303.91 | 2021-2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $268.50 | 2021-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $256.79 | 2021-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $226.12 | 2023-2025 | Omvoh, Zepbound |
| Boston Scientific Corporation | $198.72 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.98 | 2022-2023 | |
| Genzyme Corporation | $184.68 | 2023-2025 | |
| Evoke Pharma, INC. | $178.09 | 2022-2025 | Gimoti |
| Glaxosmithkline, LLC. | $176.43 | 2021-2024 | Arexvy |
| Celgene Corporation | $159.45 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $155.76 | 2021-2025 | Stelara, Tremfya |
| E.R. Squibb & Sons, L.L.C. | $154.87 | 2022-2023 | Zeposia |
| Medtronic, INC. | $115.77 | 2023 | Interstim |
| Merz North America, INC. | $108.77 | 2023 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $93.50 | 2021 | |
| Sumitomo Pharma America, INC. | $92.60 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $89.94 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $74.67 | 2024-2025 | Iqirvo |
| Esperion Therapeutics, INC. | $73.77 | 2021 | |
| Merck Sharp & Dohme LLC | $69.32 | 2021-2024 | Dificid |
| Aimmune Therapeutics, INC. | $63.18 | 2025 | Zenpep |
| Celltrion USA INC. | $50.88 | 2024-2025 | Zymfentra, Vegzelma |
| Dexcom, INC. | $48.54 | 2023 | Dexcom G7 Gss (161) |
| Qol Medical, LLC | $46.63 | 2022 | |
| Fresenius Kabi USA, LLC | $44.86 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $37.13 | 2022-2023 | Rebyota |
| Braintree Laboratories, INC. | $24.45 | 2021 | |
| Enterra Medical, INC. | $21.37 | 2025 | |
| Sandoz INC. | $18.11 | 2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.30 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.